Sino Biopharmaceutical (SBMF.F) Stock Overview
An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
SBMF.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sino Biopharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.99 |
| 52 Week High | HK$0.99 |
| 52 Week Low | HK$0.37 |
| Beta | 0.64 |
| 1 Month Change | 7.96% |
| 3 Month Change | 99.82% |
| 1 Year Change | 191.25% |
| 3 Year Change | 83.17% |
| 5 Year Change | -14.73% |
| Change since IPO | 167.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| SBMF.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.5% | 6.3% | 1.0% |
| 1Y | 191.3% | -12.3% | 17.0% |
Return vs Industry: SBMF.F exceeded the US Pharmaceuticals industry which returned -12.3% over the past year.
Return vs Market: SBMF.F exceeded the US Market which returned 17% over the past year.
Price Volatility
| SBMF.F volatility | |
|---|---|
| SBMF.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SBMF.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SBMF.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 24,379 | Eric Tse | www.sinobiopharm.com |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand.
Sino Biopharmaceutical Limited Fundamentals Summary
| SBMF.F fundamental statistics | |
|---|---|
| Market cap | US$17.87b |
| Earnings (TTM) | US$267.30m |
| Revenue (TTM) | US$4.02b |
Is SBMF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBMF.F income statement (TTM) | |
|---|---|
| Revenue | CN¥28.87b |
| Cost of Revenue | CN¥5.34b |
| Gross Profit | CN¥23.53b |
| Other Expenses | CN¥21.61b |
| Earnings | CN¥1.92b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Aug 18, 2025
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 81.51% |
| Net Profit Margin | 6.65% |
| Debt/Equity Ratio | 22.4% |
How did SBMF.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/17 14:45 |
| End of Day Share Price | 2025/08/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sino Biopharmaceutical Limited is covered by 56 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Justin Liu | BNP Paribas Securities (Asia) |
| Bo Li | BofA Global Research |